share_log

Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $28

Benzinga ·  Nov 18 21:59  · Ratings

Oppenheimer analyst Jeff Jones maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $34 to $28.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment